TLDR AbbVie is investing $1.4 billion to build a 185-acre manufacturing campus in Durham, North Carolina It’s the company’s largest-ever capital investment in aTLDR AbbVie is investing $1.4 billion to build a 185-acre manufacturing campus in Durham, North Carolina It’s the company’s largest-ever capital investment in a

AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement

2026/04/23 01:21
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • AbbVie is investing $1.4 billion to build a 185-acre manufacturing campus in Durham, North Carolina
  • It’s the company’s largest-ever capital investment in a single site
  • The campus will produce injectable medicines for immunology, neuroscience and oncology
  • 734 permanent jobs will be created over four years, plus 2,000+ construction jobs
  • Construction starts in 2026, with completion expected by end of 2028

AbbVie announced on Wednesday it will spend $1.4 billion building a new pharmaceutical manufacturing campus in Durham, North Carolina — its biggest single-site investment ever.

The 185-acre campus will sit near Research Triangle Park and serve as AbbVie’s U.S. center of excellence for small volume parenteral (SVP) manufacturing. These are sterile injectable medicines — vials, syringes and prefilled cartridges — used to treat conditions across immunology, neuroscience and oncology.

This is AbbVie’s first major footprint in North Carolina.

Construction is set to begin later this year, with the full campus expected to be operational by the end of 2028. The first phase includes manufacturing plants, labs, a warehouse, office space and employee wellness facilities.


ABBV Stock Card
AbbVie Inc., ABBV

AbbVie plans to hire 734 full-time employees over four years — engineers, scientists, manufacturing operators and lab technicians. The build will also support more than 2,000 construction jobs during development.

Part of a Broader $100 Billion U.S. Commitment

The Durham campus is one piece of a much larger picture. AbbVie has pledged to spend roughly $100 billion on U.S. research, development and manufacturing over the next decade.

In the past 12 months alone, the company has committed over $2.2 billion to U.S. manufacturing projects across North Carolina, Illinois, Arizona and Massachusetts.

Back in February, AbbVie announced a $380 million investment to build two active pharmaceutical ingredient manufacturing facilities at its North Chicago, Illinois campus, focused on neuroscience and obesity medicines.

The Durham site adds to that momentum.

Why North Carolina

AbbVie picked the Research Triangle Park area for its skilled regional workforce and room for future expansion.

When complete, the campus will supply medicines both domestically and internationally, acting as a central hub for AbbVie’s injectable drug production in the U.S.

AbbVie currently employs around 29,000 people across the U.S., including more than 6,000 at its domestic manufacturing sites. With this announcement, the company’s total U.S. job creation commitment in the past year now exceeds 1,300 new positions across four states.

The campus will also integrate AI and advanced manufacturing technologies into its operations — a detail AbbVie highlighted in its announcement.

The project represents AbbVie’s first entry into North Carolina as a manufacturing state, and the company says the site has been designed with future pipeline growth in mind.

The post AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement appeared first on CoinCentral.

Market Opportunity
4 Logo
4 Price(4)
$0.011118
$0.011118$0.011118
+1.46%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!